Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

Technology appraisal guidance
Reference number: TA285
Published: 22 May 2013

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document
19 April 2013
(282.08 Kb 22 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 16 April 2013